Active, not recruitingInterventional · Phase 1/2NCT02106598 ↗Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal MetastasesDavid I. KutlerPIInterventionDrug: fluorescent cRGDY-PEG-Cy5.5-C dotsDatesApr 2014 – Apr 2027 (est.)
Active, not recruitingInterventional · Phase 1/2NCT02773030 ↗Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple MyelomaRuben NiesvizkyPIInterventionDrug: CC-220 · Drug: Dexamethasone · Drug: Daratumumab · Drug: Bortezomib · Drug: Carfilzomib · Drug: Daratumumab - 16mg/kg · Drug: Bortezomib (BTZ) · Drug: Daratumumab- 1800mgDatesOct 2016 – May 2024· Results postedSponsorCelgene CorporationMultiple Myeloma
Active, not recruitingInterventional · Phase 1/2NCT03304080 ↗A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast CancerEleni AndreopoulouPIInterventionDrug: Anastrozole · Drug: Palbociclib · Drug: Trastuzumab · Drug: PertuzumabDatesDec 2017 – Jul 2027 (est.)SponsorIcahn School of Medicine at Mount SinaiBreast NeoplasmsBreast Diseases
Active, not recruitingInterventional · Phase 1/2NCT03331198 ↗An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)Tsiporah B ShorePIInterventionBiological: JCAR017 (lisocabtagene maraleucel) · Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib · Biological: JCAR017 (lisocabtagene maraleucel) + venetoclaxDatesNov 2017 – Nov 2027 (est.)SponsorJuno Therapeutics, Inc.Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic
RecruitingInterventional · Phase 1/2NCT03449238 ↗Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer PatientsSilvia Chiara FormentiPIInterventionDrug: PembrolizumabDatesNov 2018 – Dec 2028 (est.)SponsorWeill Medical College of Cornell UniversityMetastatic Breast CancerBrain Metastases
RecruitingInterventional · Phase 1/2NCT03556228 ↗A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or LymphomaAshish SaxenaPIInterventionDrug: VMD-928 100 mg Tablet · Drug: VMD-928 Tablet and Pembrolizumab (200 mg)DatesJun 2018 – Dec 2027 (est.)SponsorVM Oncology, llcHead and Neck CarcinomaAdenoid Cystic CarcinomaLung Cancer+22 more
Active, not recruitingInterventional · Phase 1/2NCT04041310 ↗A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsManish A ShahPIInterventionBiological: GAd-209-FSP low dose · Biological: MVA-209-FSP low dose · Biological: GAd-209-FSP high dose · Biological: MVA-209-FSP high dose · Biological: GAd20-209-FSP, RP2D · Biological: MVA-209-FSP, RP2D · Drug: KEYTRUDA®DatesOct 2019 – Oct 2026 (est.)SponsorNousCom SRLSolid Tumor, Adult
Active, not recruitingInterventional · Phase 1/2NCT04067336 ↗A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaGail J RobozPIInterventionDrug: Ziftomenib · Drug: Midazolam · Drug: ItraconazoleDatesSep 2019 – Oct 2028 (est.)SponsorKura OncologyAdvanced Malignant NeoplasmAcute Myeloid LeukemiaMixed Lineage Leukemia+4 more
Active, not recruitingInterventional · Phase 1/2NCT04068194 ↗A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesElizabeta Cristina PopaPIInterventionDrug: Avelumab · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Radiation: Hypofractionated Radiation Therapy · Drug: PeposertibDatesApr 2020 – Jul 2027 (est.)SponsorNational Cancer InstituteLocally Advanced Malignant Solid NeoplasmLocally Advanced Unresectable CholangiocarcinomaLocally Advanced Unresectable Gallbladder Carcinoma+7 more
Active, not recruitingInterventional · Phase 1/2NCT04086264 ↗A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaGail J RobozPIInterventionDrug: Azacitidine · Drug: IMGN632 · Drug: VenetoclaxDatesNov 2019 – Feb 2027 (est.)SponsorAbbVie Inc.Acute Myeloid Leukemia
Active, not recruitingInterventional · Phase 1/2NCT04127578 ↗A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)Harini SarvaPIInterventionBiological: LY3884961 · Drug: Methylprednisolone · Drug: SirolimusDatesJan 2020 – Aug 2031 (est.)SponsorPrevail Therapeutics, Inc.Parkinson Disease
RecruitingInterventional · Phase 1/2NCT04150497 ↗Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)Gail J RobozPIInterventionBiological: UCART22 · Biological: CLLS52DatesOct 2019 – Jun 2026 (est.)SponsorCellectis, IncB-cell Acute Lymphoblastic Leukemia
Active, not recruitingInterventional · Phase 1/2NCT04172532 ↗A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic AdenocarcinomaAllyson J OceanPIInterventionProcedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Radiation: Hypofractionated Radiation Therapy · Procedure: Magnetic Resonance Imaging · Drug: Peposertib · Other: Placebo AdministrationDatesJan 2021 – Aug 2027 (est.)SponsorNational Cancer InstituteLocally Advanced Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8
RecruitingInterventional · Phase 1/2NCT04176198 ↗A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary MyelofibrosisJoseph M ScanduraPIInterventionDrug: Nusivertib · Drug: Ruxolitinib · Drug: MomelotinibDatesDec 2019 – Apr 2027 (est.)SponsorSumitomo Dainippon Pharma Oncology, IncMyelofibrosis
Active, not recruitingInterventional · Phase 1/2NCT04194554 ↗A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate CancerScott T. TagawaPIInterventionDrug: Niraparib · Drug: Leuprolide · Drug: Abiraterone Acetate · Radiation: Stereotactic body radiotherapy (SBRT)DatesNov 2020 – May 2027 (est.)SponsorUniversity of MichiganProstate Cancer
Enrolling by invitationInterventional · Phase 1/2NCT04432623 ↗A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell DiseaseSujit ShethPIInterventionDrug: Benserazide Only ProductDatesOct 2020 – Feb 2026 (est.)SponsorPhoenicia BioSciences, Inc.Beta Thalassemia IntermediaSickle Cell Disease
RecruitingInterventional · Phase 1/2NCT04486352 ↗A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial CancerEvelyn CantilloPIInterventionDrug: Atezolizumab - 28 Day Cycle · Drug: Bevacizumab · Drug: Ipatasertib · Drug: Talazoparib · Drug: Trastuzumab emtansine · Drug: Tiragolumab · Drug: Atezolizumab - 21 Day Cycle · Drug: Inavolisib · Drug: Letrozole · Drug: Giredestrant · Drug: AbemaciclibDatesOct 2021 – Oct 2026 (est.)SponsorAlliance Foundation Trials, LLCEndometrial Cancer
Active, not recruitingInterventional · Phase 1/2NCT04657081 ↗A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination With Venetoclax in Adult Patients With Acute Myeloid LeukemiaGail J RobozPIInterventionDrug: Decitabine and Cedazuridine (ASTX727) · Drug: VenetoclaxDatesFeb 2021 – Sep 2024SponsorTaiho Oncology, Inc.Acute Myeloid Leukemia
Active, not recruitingInterventional · Phase 1/2NCT04730258 ↗Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMMLGail J RobozPIInterventionDrug: CFI-400945 · Drug: AzacitidineDatesApr 2021 – Jan 2026 (est.)SponsorTreadwell Therapeutics, Inc.Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+3 more
RecruitingInterventional · Phase 1/2NCT04868604 ↗A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate CancerScott T. TagawaPIInterventionDrug: 64Cu-SAR-bisPSMA · Drug: 67Cu-SAR-bisPSMADatesAug 2021 – Sep 2026 (est.)SponsorClarity PharmaceuticalProstatic Neoplasms, Castration-Resistant